Drugs Made In America Acquisition Corp
DMAA10.380USD
+0.020+0.19%
交易中 （美东）报价延迟15分钟
347.89M总市值
94.62市盈率 TTM
关于 Drugs Made In America Acquisition Corp 公司
Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues.
Drugs Made In America Acquisition Corp简介
公司代码DMAA
公司名称Drugs Made In America Acquisition Corp
上市日期Jan 28, 2025
CEOStockwell (Lynn)
员工数量- -
证券类型Ordinary Share
年结日Jan 28
公司地址1 East Broward Boulevard
城市FT LAUDERDALE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编33301
电话19548703099
网址
公司代码DMAA
上市日期Jan 28, 2025
CEOStockwell (Lynn)
Drugs Made In America Acquisition Corp公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
100.00K
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
100.00K
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Drugs Made In America Acquisition LLC
25.57%
Karpus Investment Management
7.60%
First Trust Capital Management L.P.
6.69%
Polar Asset Management Partners Inc.
5.67%
Glazer Capital, LLC
5.44%
其他
49.03%
持股股东
持股股东
占比
Drugs Made In America Acquisition LLC
25.57%
Karpus Investment Management
7.60%
First Trust Capital Management L.P.
6.69%
Polar Asset Management Partners Inc.
5.67%
Glazer Capital, LLC
5.44%
其他
49.03%
股东类型
持股股东
占比
Hedge Fund
30.25%
Corporation
25.57%
Investment Advisor/Hedge Fund
24.75%
Investment Advisor
5.74%
Research Firm
5.62%
Individual Investor
1.19%
其他
6.88%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
47
22.21M
67.76%
-8.45K
2025Q3
47
22.22M
67.76%
+1.02M
2025Q2
38
21.21M
54.90%
+2.81M
2025Q1
25
18.33M
0.00%
+18.33M
2024Q4
5
4.59M
15.73%
+4.59M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Drugs Made In America Acquisition LLC
8.57M
25.57%
+4.38M
+104.63%
Feb 25, 2025
Karpus Investment Management
2.74M
8.19%
+420.07K
+18.08%
Jun 30, 2025
First Trust Capital Management L.P.
2.24M
6.69%
+175.80K
+8.51%
Jun 30, 2025
Polar Asset Management Partners Inc.
1.90M
5.67%
--
--
Jun 30, 2025
Glazer Capital, LLC
1.82M
5.44%
-502.00
-0.03%
Jun 30, 2025
Westchester Capital Management, LLC
1.67M
4.98%
+690.00K
+70.48%
Jun 30, 2025
Hudson Bay Capital Management LP
1.80M
5.37%
--
--
Jun 30, 2025
Wolverine Asset Management, LLC
1.02M
3.05%
+418.87K
+69.46%
Jun 30, 2025
Mizuho Securities USA, LLC.
919.79K
2.74%
+919.79K
--
Jun 30, 2025
Aristeia Capital, L.L.C.
881.72K
2.63%
-18.28K
-2.03%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
CrossingBridge Pre-Merger SPAC ETF
0%
CrossingBridge Pre-Merger SPAC ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Drugs Made In America Acquisition Corp的前五大股东是谁？
Drugs Made In America Acquisition Corp 的前五大股东如下：
Drugs Made In America Acquisition LLC持有股份：8.57M，占总股份比例：25.57%。
Karpus Investment Management持有股份：2.74M，占总股份比例：8.19%。
First Trust Capital Management L.P.持有股份：2.24M，占总股份比例：6.69%。
Polar Asset Management Partners Inc.持有股份：1.90M，占总股份比例：5.67%。
Glazer Capital, LLC持有股份：1.82M，占总股份比例：5.44%。
Drugs Made In America Acquisition LLC持有股份：8.57M，占总股份比例：25.57%。
Karpus Investment Management持有股份：2.74M，占总股份比例：8.19%。
First Trust Capital Management L.P.持有股份：2.24M，占总股份比例：6.69%。
Polar Asset Management Partners Inc.持有股份：1.90M，占总股份比例：5.67%。
Glazer Capital, LLC持有股份：1.82M，占总股份比例：5.44%。
Drugs Made In America Acquisition Corp的前三大股东类型是什么？
Drugs Made In America Acquisition Corp 的前三大股东类型分别是：
Drugs Made In America Acquisition LLC
Karpus Investment Management
First Trust Capital Management L.P.
Drugs Made In America Acquisition LLC
Karpus Investment Management
First Trust Capital Management L.P.
有多少机构持有Drugs Made In America Acquisition Corp(DMAA)的股份？
截至2025Q4，共有47家机构持有Drugs Made In America Acquisition Corp的股份，合计持有的股份价值约为22.21M，占公司总股份的67.76%。与2025Q3相比，机构持股有所增加，增幅为--。
哪个业务部门对Drugs Made In America Acquisition Corp的收入贡献最大？
在--，--业务部门对Drugs Made In America Acquisition Corp的收入贡献最大，创收--，占总收入的--%。
